2-Bromo-1-chloro-4-(trifluoromethyl)benzene → (7Br,11as)-n-[2-chloro-5-(trifluoromethyl)phenyl]-1,2,7b,8,9,10,11,11a-octahydro-4h-pyrido[4,3-b][1,4]thiazepino[6,5,4-hi]indol-6-amine

참여 물질

반응 단계

Using 3-bromo-4-chlorobenzotrifluoride and following the procedures described in EXAMPLE 33, Parts C and D, tert-butyl (7bR,11aS)-6-amino-1,2,7b,10,11,11a-hexahydro-4H-pyrido[4,3-b][1,4]thiazepino[6,5,4-hi]indole-9(8H)-carboxylate from EXAMPLE 33, Part B was converted into the title compound of EXAMPLE 38 as a powder. 1H NMR(CDCl3, 300 MHz) δ 1.82-1.87 (m, 4H), 2.58-2.65 (m, 1H), 2.82-3.28 (m, 6H), 3.46-3.51 (m, 1H), 3.62-3.65 (m, 1H), 3.76 (s, 2H), 6.04 (s, 1H), 6.73 (s, 1H), 6.83 (s, 1H), 6.91 (d, 1H, J=8 Hz), 7.14 (s, 1H), 7.37 (d, 1H, J=8 Hz). LRMS (ES)+: 440 (M+H)+.

출처 및 근거